CD96 Recombinant Rabbit mAb (S-5322)

CD96, also known as TACTILE (T cell activation, late expression protein), is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily, primarily expressed on the surface of activated T cells and natural killer (NK) cells. The extracellular region of this protein contains immunoglobulin-like domains, and through binding to PVR (poliovirus receptor, CD155) on the surface of target cells, it mediates the adhesion between NK cells and target cells, playing an important role in cell-cell adhesion and signal regulation during the late phase of immune responses. Functionally, CD96 is now widely recognized as a novel inhibitory immune checkpoint. It negatively regulates the activation and cytotoxic functions of NK cells and CD8+ T cells by competing with the costimulatory receptor CD226 for binding to their shared ligand CD155, with higher affinity than CD226. Studies have shown that in various malignancies such as acute myeloid leukemia and hepatocellular carcinoma, CD96 expression on NK cells is significantly upregulated and is closely associated with dysfunction induced by immunosuppressive factors such as TGF-β1. NK cells with high CD96 expression exhibit reduced IFN-γ secretion and decreased cytotoxic activity, indicating a poor clinical prognosis. Given its critical role in tumor immune evasion, blocking the CD96-CD155 interaction has emerged as a novel strategy to enhance anti-tumor immune responses. CD96 is actively being investigated as a next-generation immune checkpoint target, offering new directions for improving the efficacy of immunotherapies.